2012 Fiscal Year Final Research Report
Development of effective blood purification treatment method usingHSA bound toxic comnpodus designed bpyhase display tecnohlogy
| Project/Area Number |
23659088
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Medical pharmacy
|
|---|
| Research Institution | Sojo University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
MARUYAMA Toru 熊本大学, 薬学部, 教授 (90423657)
WATANABE Hiroshi 熊本大学, 薬学部, 准教授 (70398220)
|
|---|
| Project Period (FY) |
2011 – 2012
|
| Keywords | アルブミン / 血液浄化法 / 分子進化工学 / 毒素中和 / ハイブリッド |
|---|
| Research Abstract |
This study was undertaken to design and evaluate recombinant albumin mutant( specially, domain II mutant)with high bilirubin (BR) binding affinity via phage display technology.The results obtained here identified the amino acid residues that interact carboxylatesof BR in HSA, and also produces HSA domain II mutants with high BR binding affinity. To our knowledge, this is the first finding on HSA mutant with enhanced binding affinity to BR. This approach could be applied to other HSA bound toxic compounds that responsible for the progression oifseadse and thereby it will pave the way for the development ofminimally invasive and low cost blood clarification method.
|
Research Products
(47 results)
-
-
-
-
[Journal Article] Pharmacokinetic alteration of (99m)Tc-MAG3 using serum protein binding displacement method.2013
Author(s)
Nishi K, Kobayashi M, Nishii R, Shikano N, Takamu ra N, Kuga N, Yamasaki K, Nagamachi S, Tamura S, Otagiri M, Kawai K.
-
Journal Title
Nucl Med Biol.
Volume: 40
Pages: 366-70
DOI
Peer Reviewed
-
[Journal Article] A human serum albumin-thioredoxin fusion protein prevents experimental contrast -induced nephropathy.2013
Author(s)
Kodama A, Watanabe H, Tanaka R, Tanaka H, Chuang VT, Miyamoto Y, Wu Q, Endo M, Hamasaki K, Ishima Y, Fukagawa M, Otagiri M, Maruyama T.
-
Journal Title
Kidney Int.
Volume: 83
Pages: 446-54
DOI
Peer Reviewed
-
-
[Journal Article] S-nitrosated α-1-acid glycoprotein kills drug-resistant bacteria and aids survival in sepsis.2013
Author(s)
Watanabe K, Ishima Y, Akaike T, Sawa T, Kuroda T, Ogaw a W, Watanabe H, Suenaga A, Kai T, Otagiri M, Maruyama T.
-
Journal Title
FASEB J.
Volume: 27
Pages: 391-8
DOI
Peer Reviewed
-
-
[Journal Article] Effect of acetaminophen on the progression of renal damage in adenine induced renal failure model rats.2012
Author(s)
Kadowaki D, Sumikawa S, Arimizu K, Taguchi K, Kitamura K, Ishitsuka Y, Narita Y, Irie T, Chuang VT, Maruyama T, Otagiri M, Hirata S.
-
Journal Title
Life Sci
Volume: 91
Pages: 1304-8
DOI
Peer Reviewed
-
-
[Journal Article] Liposome -encapsulated hemoglobin (hemoglobin-vesicle) is not transferred from mother to fetus at the late stage of pregnancy in the rat model.2012
Author(s)
Kaga M, Li H, Ohta H, Taguchi K, Ogaki S, Izumi H, Inagaki M, Tsuchiya S, Okamura K, Otagiri M, Sakai H, Yaegashi N.
-
Journal Title
Life Sci.
Volume: 91
Pages: 420-8
DOI
Peer Reviewed
-
[Journal Article] A uremic toxin, 3-carboxy-4-methyl-5-propyl-2-furanpropionate induces cell damage to proximal tubular cells via the generation of a radical intermediate.2012
Author(s)
Miyamoto Y, Iwao Y, Mera K, Watanabe H, Kadowaki D, Ishima Y, Chuang VT, Sato K, Otagiri M, Maruyama T.
-
Journal Title
Biochem Pharmacol.
Volume: 84
Pages: 1207-14
DOI
Peer Reviewed
-
-
-
[Journal Article] Interaction between two sulfate-conjugated uremic toxins, p-cresyl sulfate and indoxyl sulfate,2012
Author(s)
Watanabe H, Noguchi T, Miyamoto Y, Kadowaki D, Kotani S, Nakajima M, Miyamura S, Ishima Y, Otagiri M, Maruyama T .
-
Journal Title
Drug Metab Dispos.
Volume: 40
Pages: 1423-8
DOI
Peer Reviewed
-
[Journal Article] S-guanylation of human serum albumin is a unique posttranslational modification and results in a novel class of antibacterial agents.2012
Author(s)
Ishima Y, Hoshino H, Shinagawa T, Watanabe K, Akaike T, Sawa T, Kragh -Hansen U, Kai T, Watanabe H, Maruyama T, Otagiri M.
-
Journal Title
J Pharm Sci.
Volume: 101
Pages: 3222-9
DOI
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
